Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Performance of an established system of first responder out-of-hospital defibrillation. The results of the second year of the Heartstart Scotland Project in the 'Utstein Style'.
Sedgwick ML, Dalziel K, Watson J, Carrington DJ, Cobbe SM. Sedgwick ML, et al. Resuscitation. 1993 Aug;26(1):75-88. doi: 10.1016/0300-9572(93)90166-n. Resuscitation. 1993. PMID: 8210735
Efficacy of out of hospital defibrillation by ambulance technicians using automated external defibrillators. The Heartstart Scotland Project.
Sedgwick ML, Watson J, Dalziel K, Carrington DJ, Cobbe SM. Sedgwick ML, et al. Resuscitation. 1992 Aug-Sep;24(1):73-87. doi: 10.1016/0300-9572(92)90175-c. Resuscitation. 1992. PMID: 1332165
Chemical cardioversion of atrial fibrillation with intravenous dofetilide.
Sedgwick ML, Lip G, Rae AP, Cobbe SM. Sedgwick ML, et al. Int J Cardiol. 1995 Apr;49(2):159-66. doi: 10.1016/0167-5273(95)02284-4. Int J Cardiol. 1995. PMID: 7628887 Clinical Trial.
Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug.
Sedgwick M, Rasmussen HS, Walker D, Cobbe SM. Sedgwick M, et al. Br J Clin Pharmacol. 1991 May;31(5):515-9. doi: 10.1111/j.1365-2125.1991.tb05572.x. Br J Clin Pharmacol. 1991. PMID: 1888617 Free PMC article.
The drug exhibited first-order kinetics with a mean clearance of 4.7 +/- 1.2 ml min-1 kg-1 and a mean terminal plasma half-life of 9.7 h. 5. ...
The drug exhibited first-order kinetics with a mean clearance of 4.7 +/- 1.2 ml min-1 kg-1 and a mean terminal plasma half-life of 9. …
Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris.
Sedgwick ML, Rasmussen HS, Cobbe SM. Sedgwick ML, et al. Am J Cardiol. 1992 Feb 15;69(5):513-7. doi: 10.1016/0002-9149(92)90996-c. Am J Cardiol. 1992. PMID: 1736617 Clinical Trial.
Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris.
Sedgwick ML, Rasmussen HS, Cobbe SM. Sedgwick ML, et al. Am J Cardiol. 1992 Dec 1;70(18):1432-7. doi: 10.1016/0002-9149(92)90295-a. Am J Cardiol. 1992. PMID: 1442614 Clinical Trial.
Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris.
Sedgwick ML, Dalrymple I, Rae AP, Cobbe SM. Sedgwick ML, et al. Eur Heart J. 1995 Nov;16(11):1641-6. doi: 10.1093/oxfordjournals.eurheartj.a060790. Eur Heart J. 1995. PMID: 8881860 Clinical Trial.
Treating oral candidiasis: potentially fatal.
Evans J, Orme DS, Sedgwick ML, Youngs GR. Evans J, et al. Among authors: sedgwick ml. Br Dent J. 1997 Jun 28;182(12):452. doi: 10.1038/sj.bdj.4809409. Br Dent J. 1997. PMID: 9231515 No abstract available.
Treatment of a postoperative cholecystocutaneous fistula by an endoscopic stent.
Sedgwick ML, Denyer ME. Sedgwick ML, et al. Br J Surg. 1989 Feb;76(2):159-60. doi: 10.1002/bjs.1800760218. Br J Surg. 1989. PMID: 2702450 No abstract available.
11 results
Jump to page
Feedback